This study investigated the cardiovascular effects of the essential oil of Croton zehntneri (EOCZ) in deoxycorticosterone-acetate (DOCA)-salt hypertensive rats. Furthermore, in vitro experiments using isolated thoracic aortic rings were performed to assess the vascular effects of the EOCZ. In conscious hypertensive rats, intravenous (i.v.) injections of EOCZ (1-20 mg/kg) induced rapid (2-4 s) and dose-dependent hypotension and bradycardia (phase 1). The hypotension was followed by a significant pressor effect that was more evident at the higher doses (10 and 20 mg/kg) of EOCZ. Hypotension and bradycardia of EOCZ (phase 1) were abolished and respectively reversed into pressor and tachycardiac effects by methylatropine (1 mg/kg, i.v.) pretreatment. In isolated endothelium-intact aortic preparations, increasing concentrations (1-1000 µg/mL) of EOCZ relaxed the potassium-induced contraction in a concentrationdependent manner with an IC 50 (geometric mean [95% confidence interval]) value of 202.0 [92.0-443.7] µg/mL. This vasorelaxant effect remained unaffected by either mechanical removal of functional vascular endothelium ] µg/mL) or the addition of atropine (1 µM) .2] µg/mL) in the perfusion medium. These data show that i.v. administration of EOCZ in DOCA-salt hypertensive rats induces a vago-vagal reflex decreases in heart rate and blood pressure (phase 1). EOCZ may induce a second and delayed hypotension due to its direct endothelium-independent vasorelaxant effects, but it seems to be buffered by the pressor component (subsequent to phase 1) of EOCZ. This pattern of blood pressure and heart rate responses to EOCZ seems unaltered by DOCA-salt hypertension, as was similar to that previously reported in conscious normotensive rats.
Croton zehntneri Pax et Hoffm. (Euphorbiaceae) is an abundant aromatic plant in northeastern Brazil, where it is commonly known as "canela de cunhã". In folk medicine, infusions or decoctions of leaves from C. zehntneri are commonly used to treat anxiety, anorexia, and for the relief of gastrointestinal disturbances [1] [2] [3] . Furthermore, because C. zehntneri is characterized by a strong and pleasant odor reminiscent of anise and clove, extracts of its bark and leaves are used in perfumes and as sweeteners in foods and drinks [1, 4] . Leaves of C. zehntneri have an essential oil content of approximately 2% of the plant dry weight, comprised principally of mono-and sesquiterpenes [1, 4] . Notwithstanding, little is known about the biological actions of the essential oil of C. zehntneri (EOCZ). Previously, EOCZ has been reported to exert antispasmodic effects on Guinea-pig isolated ileum [5, 6] , justifying the use of the plant in folk medicine for the treatment of gastrointestinal disorders. Recently, EOCZ was reported to exhibit larvicidal activity against Aedes aegypti [6] and its main constituent, anethole, was reported to display a gastroprotective effect by increasing the surface mucous layer in rodents [7] .
Studying its effects on the cardiovascular system, we previously reported that i.v. injections of EOCZ induced biphasic changes in blood pressure in conscious normotensive rats [8] . Initially a rapid bradycardia occurred coincidentally with an arterial hypotension (phase 1, i.e. vagus reflex) and then, an increase in blood pressure (phase 2). Further studies performed in anesthetized rats showed that EOCZ-induced a capsaicin-like bradycardiac and depressor reflex (phase 1) which was mediated through activation of the vanilloid TPRV 1 receptors located on sensory vagal nerves [9] . Cardiovascular effects of EOCZ are mainly attributed to the actions of its two major constituent anethole (42% of essential oil weight) and estragole (46% of essential oil weight) [8, 9] .
The present study was undertaken to assess whether the pattern of blood pressure responses to EOCZ is altered in deoxycorticosterone-acetate (DOCA)-salt hypertensive, conscious rats, an experimental model in which basal sympathetic activity in enhanced [10] . Furthermore, in vitro experiments using isolated thoracic aortic rings from DOCA-salt rats were performed to assess the vascular effects of the EOCZ and the influence of mechanical removal of endothelium on these effects.
In vivo experiments:
In conscious DOCA-salt hypertensive rats, average baseline values of mean arterial pressure (MAP) and heart rate (HR)before any treatment were 172.4 ± 4.6 mmHg and 371 ± 15 beats/min, respectively (pooled data from 11 rats). There was no significant cha nge in either baseline MAP or HR after i.v. administration of EOCZ's vehicle (Tween 80) (data not shown), as well as EOCZ at 1 mg/kg (Figure 1 ). However, increasing bolus injection of EOCZ (5, 10 and 20 mg/kg, i.v.) evoked rapid and dose-dependent (P < 0.001) decreases in MAP ( Figure 1A ) and HR ( Figure 1B) , which became significant (P < 0.05) at the dose of 5 mg/kg (Figure 1 ). These rapid HR and MAP effects, identified as phase 1, occurred within about 2-4 s after the injection of EOCZ (Figure 1 , panels C and D, respectively). At the higher doses (10 and 20 mg/kg) of EOCZ, the phase 1 hypotensive and bradycardiac effects were followed by the phase 2, characterized by a significant (P < 0.05) pressor response ( Figures 1D, 2A ) associated by a second period of bradycardia ( Figures 1C, 2B) , which peaked at 15-20 s ( Figures 1C, 1D significant (P < 0.05) pressor ( Figure 1A ) and tachycardiac ( Figure  1B ) effects, respectively. The delayed bradycardia (phase 2) was not recorded in methylatropine-pretreated rats (data not shown).
In vitro experiments:
In aortic rings with intact endothelium from DOCA-salt hypertensive rats, increasing concentrations of EOCZ (1-1000 µg/mL) inhibited the KCl-induced contractions in a concentration-dependent manner (P < 0.001). The first inhibitory effect of EOCZ became significant (P < 0.05) at a concentration of 100 µg/mL, while its maximal relaxation effect (0.48 ± 1.18% of In the present study, i.v. administration of EOCZ in conscious DOCA-salt hypertensive rats induced an initial rapid bradycardia (onset time of 2-4 s), which occurred coincidentally with arterial hypotension (phase 1). This phase 1 was followed by a second phase (named phase 2) characterized by an increase in blood pressure associated with a second, more lasting bradycardia. This pattern of responses is not different from that previously observed in conscious, normotensive rats [8] . All these effects were reversible, excluding therefore the possibility that they might have been related to a putative toxic effect of the EOCZ. In fact, EOCZ could be classified in the group of slightly toxic substances on the basis of classification of chemical substances because the LD 50 value for oral acute toxicity of EOCZ was found to be greater than 2,500 mg/kg [6, 11] . To the best of our knowledge, this is the first time that such cardiovascular effects of EOCZ have been reported in DOCA-salt hypertensive, conscious rats.
Our previous investigation in normotensive rats [9] showed that both bilateral vagotomy and perineural treatment with capsaicin abolished the initial depressor and bradycardiac response (phase 1) to EOCZ and its main constituents anethole and estragole. EOCZ induced a capsaicin-like bradycardiac and depressor reflex that was mediated through activation of the vanilloid TRPV 1 receptors located on sensory vagal nerves, as it was blocked by i.v. pretreatment with the TRPV 1 antagonist capsazepine [9] . This vagovagal reflex is attributed, in part, to the actions of anethole and [9] , which share some structural similarities with capsaicin, the pungent ingredient of hot peppers. The present study shows that in DOCA-salt hypertensive rats pretreated with vehicle, the time to occurrence of the phase 1 reductions in HR and MAP elicited by EOCZ was about 2-4 s. These responses were simultaneously blocked by i.v. pretreatment with methylatropine, indicating that a peripheral cholinergic mechanism is involved in their mediation. They occurred as rapidly as the vago-vagal responses elicited by i.v. injection of EOCZ [8] , capsaicin [12] or the 5-HT 3 receptor agonist serotonin [13] in normotensive rats. This suggests that in DOCA-salt hypertensive rats EOCZ also stimulates primary sensory vagal afferents from the heart or lungs to elicit vago-vagal reflex decreases in HR and blood pressure. It is noteworthy that this vago-vagal reflex of EOCZ in hypertensive rats was of the same order of magnitude as that observed in awake normotensive rats [8] . It is well known that ACh causes generalized vasodilatation, which is an indirect effect mediated by released nitric oxide (NO) from vascular endothelial cells [14] . The muscarinic receptor mediating relaxation of vascular smooth muscle, through released NO, is the M 3 subtype [15] . One might have suggested that the initial hypotension elicited by EOCZ would have been related to an active vascular relaxation mediated by an endothelial L-arginine/NO pathway through peripheral muscarinic receptor activation. However, such a possibility seems unlikely since the present in vitro findings show that the vasorelaxant effects of EOCZ (i) remained unaffected by pretreatment with atropine in endothelium-intact aortic preparations, and (ii) were also unaffected after the blockade of the endothelial function by removal of endothelium indicating that they are mediated rather by an endothelium-independent mechanism, as previously reported for anethole [16] . In view of its direct vasorelaxation effects, EOCZ may have, therefore, induced a delayed hypotension (subsequent to phase 1). However, this delayed hypotension seems to be buffered by the pressor component (phase 2) recorded at the higher doses of EOCZ which was more evidenced in animals pretreated with methylatropine. At the present time, the mechanism of this pressor effect is unclear and requires further investigation. Nevertheless, the present in vitro data exclude the possibility that such a pressor component may be related to a putative vasoconstriction action of EOCZ since contractile responses to KCl were not enhanced by EOCZ at any concentration used in endothelium-intact aortic preparations either incubated or not with atropine.
The delayed bradycardia concomitant with the pressor effect (phase 2) was prevented by methylatropine pretreatment, an effect suggestive of cardiac M 2 -muscarinic receptor stimulation. Although the increase in MAP elicited by EOCZ at 10 mg/kg was very transient (1 min), the delayed bradycardia remained statistically significant during a 5-min recording period. The opposite was observed for the phase 2 pressor effect and delayed bradycardia elicited by 20 mg/kg EOCZ (Figure 2 ). This finding points to independent mechanisms for the EOCZ-induced pressor effect and delayed bradycardia and precludes any possibility that the EOCZinduced delayed bradycardia resulted from the concomitant increase in MAP through an activation of the baroreflex.
The present study shows for the first time that i.v. treatment of conscious, DOCA-salt hypertensive rats with EOCZ induces an initial fall in blood pressure which is mediated by a cholinergic mechanism and seems mainly to result reflexly from the concomitant pronounced bradycardia (phase 1, i.e. vago-vagal reflex). EOCZ may induce a delayed hypotension due its endothelium-independent vasorelaxation, but it seems buffered by the pressor component (phase 2) subsequent to the EOCZ-induced vago-vagal reflex. This pattern of blood pressure and HR responses to i.v. EOCZ was unaltered by DOCA-salt hypertension as it was similar to that observed previously in awake, normotensive rats [8] . Extraction and chemical analysis: EOCZ was obtained as previously described [8] . EOCZ had the following chemical composition (% of total oil weight): estragole (45.9), anethole (42.1), germacrene-B (4.8), trans-caryophyllene (1.5), 1,8-cineole (1.2) and another 7 minor identified constituents (4.0). These compounds were identified using a mass spectral library search and 13 C NMR spectroscopy [17] .
Solutions and drugs:
For in vivo experiments, EOCZ was dissolved in Tween 80 (2%, v/v), brought to the chosen volume with sterile isotonic saline and sonicated just before use. For in vitro experiments, EOCZ was prepared directly in the perfusion medium, which was a fresh modified Tyrode solution (pH 7.4) [8] of the following composition (mM): NaCl 136, KCl 5, MgCl 2 0.98, CaCl 2 2, NaH 2 PO 4 0.36, NaHCO 3 11.9, and glucose 5.5. All drugs were purchased from Sigma and dissolved in distilled water.
Animals:
Male Wistar rats weighting 220-250 g were used. They were cared for in compliance with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication 85-23, revised 1996). All procedures described here were reviewed by and had prior approval from local animal ethics committee.
In vivo experiments:
Under ether anaesthesia, rats (n = 11) were subjected to unilateral nephrectomy. After a 1-week recovery, they were treated weekly with subcutaneous injections of DOCA (25 mg/kg) dissolved in olive oil (vehicle), and salt was administered by substitution of 1% NaCl solution for drinking water ad libitum. Circulatory and in vitro experiments were performed 4 weeks after the initiation of DOCA-salt treatment. On the last day of treatment, rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and two catheters were implanted in the abdominal aorta (for the recording of arterial blood pressure) and in the inferior vena cava (for drug administration), as previously described [8] . Twenty-four h later, baseline MAP and HR were recorded on a Gilson model 5/6H polygraph (Medical Electronics Inc., Middletown, WI, USA), as previously described [8] . The maximal changes in MAP and HR elicited by i.v. injections of increasing bolus (100 µL) doses of EOCZ (1-20 mg/kg) were determined in conscious rats, which had been pretreated intravenously 10 min earlier with either vehicle (1 mL/kg, n = 6) or methylatropine (1 mg/kg, n = 5) [18] .
In vitro experiments:
In another set of experiments, rats were stunned and then exsanguinated. Thoracic aortae were removed and cut into cylindrical strips (1 x 5 mm), which were mounted in 10 mL organ paths containing aerated Thyrod's solution at 37°C, (pH 7.4) and were stretched with a passive tension of 1 g. Tension was recorded using an isometric transducer (Grass Model FT03, Quincy, MA, USA) connected to a PC-based Dataq acquisition system (PM-100, CWE Inc., Akron, OH, USA). The vasorelaxant effects of EOCZ (1-1000 µg/mL) in intact (n = 5) or denuded (n = 5) aortic preparations were studied according to a previously described protocol [8] . The vascular effects of EOCZ (1-1000 µg/mL) were also studied in endothelium-intact preparations incubated 20 min earlier with atropine (1 µM, n = 6). Contraction data were expressed as a percentage of the potassium-induced contraction. 
